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Aurora A kinase (AURKA) is a major regulator of mitosis and an important
driver of cancer progression. The roles of AURKA outside of mitosis, and
how these might contribute to cancer progression, are not well understood.
Here, we show that a fraction of cytoplasmic AURKA is associated with
mitochondria, co-fractionating in cell extracts and interacting with mitochon-
drial proteins by reciprocal co-immunoprecipitation. We have also found
that the dynamics of the mitochondrial network are sensitive to AURKA
inhibition, depletion or overexpression. This can account for the different
mitochondrial morphologies observed in RPE-1 and U2OS cell lines,
which show very different levels of expression of AURKA. We identify
the mitochondrial fraction of AURKA as influencing mitochondrial
morphology, because an N-terminally truncated version of the kinase that
does not localize to mitochondria does not affect the mitochondrial network.
We identify a cryptic mitochondrial targeting sequence in the AURKA
N-terminus and discuss how alternative conformations of the protein may
influence its cytoplasmic fate.1. Introduction
Aurora A kinase (AURKA) was discovered as a mitotic kinase with a key role in
bipolar spindle formation [1]. Its prominent localization to the microtubule
spindle in mitosis is mediated through interaction of its kinase domain with
the microtubule-associated protein TPX2 [2], an interaction that also activates
the kinase activity of AURKA through stabilization of the active conformation
of the T-loop [3]. Further studies have revealed the existence of alternative path-
ways to activation of AURKA [4–6] and an extensive array of cellular functions
regulated by AURKA, in interphase as well as mitosis (reviewed in [7]). One
such novel function that has been described for AURKA is the promotion of
mitochondrial fission in preparation for mitosis [8].
Mitochondria form a highly dynamic network of interconnected tubules
that undergo constant cycles of fission and fusion. These cycles are an essential
feature of cellular homeostasis, thought to maintain a healthy mitochon-
drial population by allowing segregation of damaged mitochondria into the
mitophagy pathway [9,10]. It is also proposed that fission/fusion cycles
regulate the metabolic output of the cell, because a more interconnected
network provides more efficient oxidative metabolism, and that mitochon-
drial morphology responds to metabolic cues. Mitochondrial morphology
depends on the activity of GTPases dynamin-related protein 1 (Drp1) for
rsob.royalsocietypublishing.org
Open
Biol.8:170272
2fission and mitofusins (MFN1, MFN2) for fusion of the outer
mitochondrial membrane (OMM) [11,12].
Mitochondrial fission also occurs prior to cell division in
mammalian cells. Fragmentation of organelle networks
(mitochondria, Golgi, ER) is a common feature of cell
division, thought to improve the probability that organelles
segregate equally between daughter cells [13,14] and to
enable regulated segregation of aged mitochondria during
stem cell-like divisions [15]. Mitochondrial fragmentation
in mitosis may also be required for efficient microtubule-
dependent transport of mitochondria towards the cell peri-
phery and away from the cell division plane [16]. Indeed,
blocking mitochondrial fission or transport gives rise to
cytokinesis failure and aneuploidy [11,17,18], an effect that
can be rescued by disrupting mitochondrial fusion [19].
Previous studies have described a pathway leading to increased
mitochondrial fission at mitotic entry via Cdk1-dependent acti-
vation of Drp1 at the OMM [13]. The mitotic kinase AURKA
has been proposed to regulate these events through phosphoryl-
ation of RalA to promote RalA-dependent OMM recruitment of
both Drp1 and RalBP1–cyclinB–Cdk1 complex [8].
Fragmented mitochondrial networks are a characteristic
of cancer cells thought to contribute to the metabolic changes
that accompany tumorigenesis, and have been shown to
contribute to tumour progression and metastasis [20–22].
Overexpressed AURKA (located on the 20q amplicon) is
also strongly associated with cancer [23,24]. Given a large
number of mitochondrial hits we identified in a search for
AURKA interactors, we decided to investigate further the
role of AURKA in influencing the fragmentation state of
the mitochondrial network in human cell lines. We report
here that the mitochondrial network is sensitive to AURKA
activity at all phases of the cell cycle, and that this sensitivity
contributes to divergent mitochondrial morphology between
two cell lines (one transformed and the other non-
transformed) expressing different levels of AURKA. Further-
more, we identify an interphase subpopulation of AURKA
associated with mitochondria, both by immunofluorescence
and fractionation assays. This association depends on the
AURKA N-terminal region, which contains a cryptic
mitochondrial targeting sequence.2. Results and discussion
In using proteomic approaches to identify co-purifying
proteins in AURKA-GFP pulldowns from human U2OS
cells, we identified large numbers of mitochondrial proteins
(electronic supplementary material, figure S1A). We con-
firmed these potential interactions by reciprocal pulldowns
of several GFP-tagged mitochondrial markers, including the
OMM translocase complex components TOMM20 and
TOMM70 and the inner mitochondrial membrane component
Prohibitin (PHB), which identified endogenous AURKA as a
partner protein in cell extracts (electronic supplementary
material, figure S1B). Repeated experiments suggested that
the quantity of AURKA in pulldowns of mitochondrial pro-
teins was at least 10-fold less than that found in pulldowns
of TPX2, a major interactor of AURKA in mitotic cells [2].
Given the previous study suggesting that mitochondrial
fission was controlled by a cytoplasmic pool of AURKA [8],
we investigated the relevance of our own finding—of the
association of AURKA with mitochondrial proteins—tomitochondrial morphology. First, we tested whether
depletion of endogenous AURKA, using siRNA-mediated
knockdown (AURKA-i), would affect mitochondrial mor-
phology in the immortalized retinal pigment epithelial line
hTERT-RPE-1 (RPE-1). We found that AURKA-i resulted in
markedly reduced fragmentation of the mitochondrial net-
work, observable as a more interconnected network and
quantifiable as a change in length distribution of individual
mitochondria (figure 1a; electronic supplementary material,
figure S2A, B). To confirm the specificity of this effect, we
treated RPE-1 cells, expressing an endogenous mRuby-
PCNA marker to distinguish cell cycle phases [25], with the
small-molecule-specific inhibitor of AURKA, MLN8237. We
found that the length of mitochondria varied with cell cycle
phase as expected [13,26], being shortest in G1 phase
(figure 1b), but that AURKA inhibition led to elongation of
mitochondria in all cell cycle phases (figure 1c). Therefore,
we conclude that AURKA can regulate mitochondrial organ-
ization throughout the cell cycle. To determine whether this
response of mitochondria to AURKA is a conserved role
of the kinase, we treated cultured Drosophila melanogaster
D.mel-2 cells with MLN8237 (figure 1d ). The increase in
mitochondrial connections and length following treatment
suggest that this role for AURKA is conserved in metazoans.
We noticed that cancer cell lines used in our laboratory
(e.g. U2OS) had mitochondrial networks in a more fragmen-
ted state than non-transformed RPE-1 cells (figure 2a; see also
electronic supplementary material, figure S2). Given our find-
ing that AURKA influences mitochondrial morphology, and
the well-documented overexpression of AURKA in cancer
cells, we tested whether AURKA expression levels might con-
tribute to differences in mitochondrial morphology observed
between RPE-1 and U2OS cells. We determined relative
expression levels in extracts prepared from known numbers
of cells in asynchronous populations, normalized against a
panel of cellular proteins (figure 2b). This revealed that
U2OS cells contain twofold higher levels of AURKA protein
normalized against cell number, and fourfold to sixfold more
when normalized against the levels of tubulin, actin or
ATP5A1. Therefore, higher AURKA levels correlate with a
more fragmented mitochondrial network. Next, we tested
whether manipulating AURKA levels would reproduce
observed patterns of mitochondrial organization. We used
partial siRNA-mediated knockdown to achieve sixfold
reduction of AURKA levels in U2OS cells, and found a
corresponding lengthening of mitochondria under these
conditions (figure 2c,d). Connectivity of the network was
also greater when AURKA levels were reduced. Conversely,
we found that tetracycline-induced overexpression of a
stable AURKA-Venus transgene in RPE-1 cells resulted in
a small but significant decrease in the length of mitochondria
(figure 2e,f ). In further experiments, we found that transient
overexpression of AURKA-Venus in another untransformed
line, breast epithelial MCF10A cells, also led to increased
fragmentation of the mitochondrial network in cells over-
expressing AURKA (electronic supplementary material,
figure S2C). Finally, MLN8237 treatment of HCC1143 cells,
a breast cancer line characterized by a highly fragmented
mitochondrial network, caused an increase in mitochondria
length (electronic supplementary material, figure S2D).
Therefore we conclude that the different fragmentation
state of the mitochondrial network in different cell lines is
influenced by AURKA expression.
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Figure 1. AURKA is a constitutive regulator of the mitochondrial network. (a) RPE-1 cells were treated with control (GL2-i) or AURKA siRNA (AURKA-i) for 48 h and
mitochondria imaged in live cells using MitoTrackerTM. Areas of cytoplasm marked by white squares are shown enlarged twofold in panels to the side of each image.
Mitochondria were analysed for tubular fragment length as described in Material and methods, with raw measurements shown as probability density plots. p, 0.001 for
the maximum deviation D ¼ 0.40 (K-S test). (b,c) RPE-1-mRuby-PCNA cells were stained with Mito-IDw green and imaged after treatment with 100 nM MLN8237 (MLN)
or vehicle control (DMSO) for 3 h. (b) Tubular mitochondrial lengths are plotted as probability density curves (left-hand panel) for cells assigned to G1, S or G2 phase
according to localization of mRuby-PCNA (middle panel), with cell cycle distribution summarized in the plot shown in the right-hand panel. (c) Probability density plots
showing increased mitochondria length in all phases of the cell cycle after MLN treatment. G1: p, 0.001, D ¼ 0.39; S: p, 0.001, D ¼ 0.23; G2: p, 0.001, D ¼ 0.13
(K-S test). (d ) Drosophila D.mel-2 cells were treated with MLN for 3 h and processed as in (a). p, 0.001, D ¼ 0.53 (K-S test). For panels (b–d): raw measurements are
pooled from three statistically reproducible experimental repeats. For panels (a–d): scale bars, 10 mm in main panels, 1 mm in magnification panels.
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Figure 2. AURKA levels influence mitochondrial morphology in RPE-1 and U2OS cells. (a) RPE-1 and U2OS cells were treated with MitoTrackerTM and imaged under
identical conditions. Mitochondrial lengths were measured and plotted as in figure 1. p, 0.001 for the maximum deviation D ¼ 0.37 (K-S test) from two repeats.
(b) Equal numbers of U2OS and RPE-1 cells were harvested for cell extracts and calculated quantities loaded onto gels to be examined by quantitative immunoblot.
Bar charts show AURKA levels quantified and normalized against number of cells, or against different loading markers. Statistical confidence is indicated as *p,
0.01; **p, 0.001 (Student’s t-test), n ¼ 3 repeats. (c,d) U2OS cells were treated with control (GL2-i) or AURKA siRNA (AURK-i) for 48 h and then either processed
for quantitative immunoblotting of AURKA levels (c) or stained with MitoTrackerTM (d ). Example images show insets indicated by white boxes magnified twofold.
Mitochondrial tubular length measurements are plotted as probability density curves. p, 0.001, D ¼ 0.73 (K-S test). (e,f ) RPE-1-AURKA-Venus cells were induced
for AURKA-Venus expression (AURKA OE) or not (control) with addition of tet for 18 h. Cells were either processed for quantitative immunoblotting of AURKA levels
(e) or stained with MitoTrackerTM for mitochondrial tubular length measurements ( f ), p, 0.01, D ¼ 0.08 (K-S test). tet, tetracycline; endog, endogenous;
OE, overexpression. For panels (a,d,f ): scale bars, 10 mm in main panels, 1 mm in magnification panels.
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Figure 3. A mitochondrial fraction of AURKA. (a) U2OS and U2OS-AURKA-Venus cells were fractionated by serial centrifugation and probed for the presence of
exogenous (exog) and endogenous (endog) AURKA, and of specific markers for cytosolic (GAPDH, MEK1) or mitochondrial (ATP5A1) fractions, by immunoblot.
(b) Co-localization of endogenous AURKA (green) and mitochondrial marker TOMM20 (red) examined by IF in RPE-1 cells. (c) Live cell imaging of endogenously
tagged RPE-1 mVenus-AURKA knock-in (KI) cells stained with MitoTrackerTM to examine co-localization. (d ) RPE-1-AURKA-Venus cells were treated with MitoTrack-
erTM 24 h after induction of AURKA-Venus expression, then methanol-fixed, stained using GFP antibody and imaged on an OMX system. The image shown is a
maximum-intensity projection of a 12  0.125 mm stack, with 10-fold magnification of insets. For panels (b,c): scale bars, 10 mm in main panels, 1 mm in
magnification panels. For panel (d ): scale bars, 10 mm in main panels, 100 nm in magnification panels.
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5Given the prevalence of mitochondrial hits in our AURKA
interactome, and the functional relationship between AURKA
and mitochondrial organization, we hypothesized that part of
the cytoplasmic pool of AURKA might be associated with the
mitochondrial network. In support of this, we found that both
endogenous and exogenous AURKA co-purify with mitochon-
dria in extracts fractionated by centrifugation (figure 3a). We
also examined fixed cells for co-localization of endogenous
AURKA with a mitochondrial marker, TOMM20. Immuno-
staining with two different antibodies against AURKA
revealed punctate cytoplasmic staining in which the AURKA
‘dots’ were frequently apposed to mitochondria, often close
to points of mitochondrial constriction (figure 3b). We then
sought to confirm that these dots were AURKA-specific
using siRNA to deplete endogenous AURKA. This led to the
reduction of the punctate staining associated with mitochon-
dria in accord with the downregulation of AURKA byAURKA-i treatment (electronic supplementary material,
figure S3A, B). We sought to confirm our finding in live
cells, by examining the cytoplasmic localization of AURKA-
Venus without fixation. When AURKA-Venus was expressed
exogenously from a transgene (as in figure 2e, also electronic
supplementary material, figures S2C, S4A), levels of cyto-
plasmic AURKA were too high to distinguish co-localization
patterns in the high cytoplasmic background. To circumvent
this issue, we targeted one allele of endogenous AURKA
at the C-terminus with mVenus, taking advantage of rAAV-
mediated homologous recombination (electronic supple-
mentary material, figure S3C). Endogenous mVenus-tagged
AURKAwas expressed to the same level as untagged endogen-
ous AURKA, was comparably enriched in cells arrested in
mitosis (electronic supplementary material, figure S3D, E) and
faithfully recapitulated the known localization of untagged
AURKA in the cell cycle (electronic supplementary material,
rsob.royalsocietypublishing.org
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6figure S3F). When we examined endogenous AURKA-
mVenus, we could detect a similar pattern of co-localization
of cytoplasmic dots of Venus fluorescence with constrictions
in mitochondria in the living cells as we had seen when
staining fixed cells for endogenous AURKA (figure 3c).
Finally, we carried out super-resolution microscopy on an
OMX system and used three-dimensional reconstruction of
Z-stacks to confirm that punctate GFP-labelled structures in
fixed RPE-1-AURKA-Venus cells frequently coincided with
constrictions in the mitochondrial network (figure 3d ). There-
fore, we concluded that a small fraction of cytoplasmic
AURKA resides at mitochondria.
The interaction we identified between translocase of the
outer membrane (TOM) complex components and AURKA
raised the possibility that AURKA might be targeted to mito-
chondria through a mitochondrial targeting sequence (MTS)
[27,28]. These are characterized by an amphipathic helix at
the N-terminus. The known structure of AURKA [29] excludes
the N-terminal region, which is generally considered to be
unstructured. We tested if AURKA lacking its N-terminal 31
amino acids (AURKAD31) would still localize in the mitochon-
drial fraction in cell fractionation experiments, and we found
that it did not (figure 4a,b). Moreover, AURKAD31 overexpres-
sion did not cause fragmentation of mitochondria (figure 4c).
We concluded that the N-terminal region of AURKA contains
sequences necessary for its localization with mitochondria
and that this localization is required for mitochondria to frag-
ment in response to the kinase’s activity. To further test this
idea, we fused an MTS onto the N-terminus of AURKAD31.
As predicted, expression of this gene fusion restored fragmen-
tation of mitochondria (electronic supplementary material,
figure S4A, B).
These findings led us to ask whether the natural
N-terminal domain of AURKA had any of the characteristics
of MTSs. We found that AURKA’s N-terminal region is
indeed polybasic and has the periodic hydrophobicity consist-
ent with that of an amphipathic helix (figure 4d). This
predicted amphipathic helix is a phylogenetically conserved
secondary feature, even where the primary amino acid (AA)
sequence diverges (electronic supplementary material, figure
S4C). When we analysed the AURKA sequence using the
bioinformatic algorithms, TargetP and MitoProt [31,32], we
identified a ‘cryptic’ targeting sequence from AA 7–55. That
is, whereas the full-length AURKA sequence was not predicted
to localize to mitochondria, in silico removal of the first 6 AAs
from its N-terminus generated a predicted mitochondrial local-
ization signal (probability in MitoProt, p. 0.95; figure 4e).
Therefore, we tested the prediction that N-terminally clipped
versions of AURKA, AURKAD6 and AURKAD8, should
localize more strongly to the mitochondrial network than the
full-length protein. Comparing the localization of AURKA-
Venus with AURKAD6/D8-Venus in fixed cells, we found
that in both RPE-1 and U2OS cells, the clipped versions
showed a more prominent co-localization with mitochondria,
consistent with the presence of cryptic mitochondrial
targeting information in the AURKA N-terminus (figure 4g;
electronic supplementary material, figure S5). Moreover,
mitochondrial fragmentation was also enhanced in the pres-
ence of AURKAD6/D8-Venus, supporting the idea that
mitochondrial targeting of AURKA promotes mitochondrial
fission (figure 4f).
A large number of proteins are described to interact with
AURKA [33]. Some of these interactions may depend uponalternative conformations of the N-terminus. Thus, for
example, the so-called A-box region can mediate interactions
with either the APC/C cofactor Cdh1 or with Calmodulin, in
a manner that may be regulated by phosphorylation on
Ser51 [5,34]. We suggest that factors affecting the folding of
the N-terminal region of AURKA could determine the localiz-
ation and fate of the kinase by directing alternative interactions.
One form of AURKA in this conformational space would dis-
play a functional MTS to mediate its mitochondrial targeting.
This conformation would be favoured by AURKAD6.
Is AURKA on the surface of mitochondria, as predicted
by its known role in promoting Drp1-mediated fission, or
on the inside, as predicted by its MTS? Studies of mitochon-
drial regulation by mitotic cyclin-dependent kinase (Cdk)
activity point to roles for cyclinB1–Cdk1 both at the mito-
chondrial surface, in regulating Drp1 activity [8], and—in a
different study—inside the mitochondrial matrix, in regulat-
ing the respiratory chain via Complex I phosphorylation
[35]. The targeting sequence on AURKA suggests that it
would be translocated into the mitochondria via the TOM
complex. Indeed, we have found direct interaction with the
TOMM20 and TOMM70 members of this complex and also
identified ATP5A subunits and other matrix components in
our proteomic survey of AURKA interactors (electronic
supplementary material, figure S1A).
The ‘MAGIC’ pathway, recently described by the Rong Li
laboratory, diverts aggregation-prone proteins into mitochon-
dria by an unknownmechanism that results in their ubiquitin-
independent clearance by mitochondrial proteases [36]. It
is possible that AURKA is an aggregation-prone protein,
given the unstructured nature of its extended N-terminus.
Exogenously expressed proteinwould bemore likely to be pro-
cessed via this pathway than endogenous proteins, because it
would be more likely to be expressed in the absence of the cor-
rect binding partners, and we certainly cannot exclude that this
pathway is responsible for co-localization ofAURKAwithmito-
chondria. However, both endogenous and exogenous AURKA
localize in the sameway, presumably sharing the pathway that
contributes to the dynamics of the mitochondrial network.
Mitochondrial fragmentation is accompanied by increased
glycolysis and decreased oxidative phosphorylation, metabolic
changes that are thought to play a critical role in cell fate
decisions (discussed in [37]). A switch to high glycolytic flux
and low oxidative metabolism is a condition for reprogram-
ming of iPS cells, with the state of high pluripotency being
characterized by a fragmented mitochondrial network. It has
been reported that AURKA is upregulated in reprogramming
of iPS cells, although—curiously—inhibition of AURKA
appears to enhance the process [38]. Our finding that the mito-
chondrial network is sensitive to AURKA levels in different
cell types highlights the importance of elucidating the
non-mitotic roles of AURKA in order to fully understand its
contributions to cell proliferation and to cancer.3. Material and methods
3.1. Plasmids
pVenus-N1-AURKA has been previously described [39]. Del-
etion mutants were made via PCR using 50 oligos as follows:
D31: GAGGTACCATGCCTTGTCAGAATCCATTACC
D6: ATGGTACCACCATGAACTGCATTTCAGGAC
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Figure 4. A cryptic mitochondrial targeting sequence resides in the AURKA N-terminus. (a,b) U2OS cells transiently transfected with AURKA-Venus (AURKA),
N-terminally truncated AURKA (AURKAD31) or Venus alone were fractionated and probed by immunoblot (a) for the presence of Venus (anti-GFP) or with various
markers for cytosolic (MEK1, PI31) and mitochondrial (ATP5A1, TOMM20) fractions. SUG1 was used to control for whole-cell lysate (WCL). Venus levels in the
mitochondrial fraction (Mito) were quantitated and normalized against the level in WCL (b) in three separate experiments. **p, 0.01; ***p , 0.001 (Student’s
t-test). (c) N-terminally truncated AURKA (D31) does not cause fragmentation of the mitochondrial network. RPE-1 cells transfected with Venus-tagged AURKA, full-
length and -D31, or Venus control, were treated with MitoTrackerTM and imaged under identical conditions. Mitochondrial tubular lengths are plotted as probability
density curves. The two-sample K-S tests of AURKA and AURKAD31 populations give p, 0.001 for maximum deviation D ¼ 0.34, from two repeats. (d ) Likely
amphipathic helix in the AURKA N-terminus revealed by Kyte–Doolittle plot (left-hand panel) and Helical wheel projection (right-hand panel) [30]. Yellow, hydro-
phobic; blue and purple, hydrophilic; grey, neutral. (e) MitoProt prediction of mitochondrial targeting probability [31] for in silico sequential N-terminal truncations
of AURKA. ( f,g) RPE-1 cells were transfected with wild-type or N-terminally truncated versions of AURKA-Venus (D6, D8) and imaged 24 h later after staining with
MitoTrackerTM for measurements of mitochondrial tubular length ( f ). By two-sample K-S tests, WT versus D6: p, 0.001, D ¼ 0.13; WT versus D8: p, 0.001,
D ¼ 0.25. Cells were then fixed and processed for IF with GFP and TOMM20 antibodies (g, see also electronic supplementary material, figure S5). For panel (g):
scale bars, 10 mm in main panels, 1 mm in magnification panels.
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8D8: TAGGTACCACCATGATTTCAGGACCTGTTAAGG
with 30 oligo CAGTAGGATCCGACTGTTTGCTAGCTG,
and insertion via Kpn1 and BamH1 sites into pVenus-N1.
An MTS from yeast TOMM70 was generated by PCR of the
pMito-mCherry-FRB template [40] with oligos 50: GCCCTC-
GAGATGAAGAGCTTCATTAC, 30: CGAGGTACCCTGTT-
GCAATTGGTTG, and inserted between Xho1 and Kpn1
sites of AURKA-D31-Venus to make MTS-AURKA-D31-
Venus. pcDNA5-FRT/TO-AURKA-Venus was made
from pcDNA5TM/FRT/TO (Thermo Fisher Scientific) with
HygromycinR sequences replaced by NeomycinR.
3.2. Cell culture and treatments
hTERT-RPE-1 (RPE-1) cells, RPE-1 FRT/TO-derived lines
[25,41] and MCF10A cells were cultured in a 50 : 50 mix of
Ham’s F12 : DMEM medium, U2OS cells were cultured in
high-glucose DMEM and HCC1143 in RPMI-1640 (all from
Thermo Fisher Scientific). Cell culture media were sup-
plemented with fetal bovine serum (FBS) at 10% (RPE-1,
U2OS, HCC1143) or 5% (MCF10A), and with penicillin–
streptomycin and amphotericin B. MCF10A cell culture was
additionally supplemented with 10 mg ml21 insulin,
0.5 mg ml21 hydrocortisone and 20 ng ml21 recombinant
EGF. All cells were grown in a humidified atmosphere
containing 5% CO2 at 378C.
RPE-1-mRuby-PCNA cells were previously described
[25]. RPE-1-AURKA-Venus (Flp-In) lines were derived as
polyclonal populations by pooling cells transfected with
pcDNA5-FRT/TO-AURKA-Venus and Flp-recombinase
(pOG44) after 12 days of selection in 500 mg ml21 geneticin.
Expression of AURKA-Venus is achieved by supplementing
cell culture medium with 1 mg ml21 tetracycline (tet; Calbio-
chem, San Diego, CA, USA). U2OS-AURKA-Venus cells
were obtained by clonal selection with 170 mg ml21 hygromy-
cin B (Calbiochem) after transfection of U2OS tet-OFF cells
with pTRE-AURKA-Venus : pCMVhygro in a ratio of 10 : 1.
Expression of AURKA-Venus in these cells is achieved with
extensive washing in PBS and switching to tet-free cell culture
medium. To generate the AURKA-mVenus knock-in, RPE-1
FRT/TO cells were infected with recombinant adeno-associ-
ated virus particles harbouring mVenus cDNA flanked by
approximately 1500 bp homologous to the AURKA locus as
previously described [42]. To identify positive integrands,
cells were treated with 10 mM DMA 12 h before single-cell
sorting by flow cytometry. mVenus-positive cells were verified
by fluorescence microscopy and immunoblot analysis (elec-
tronic supplementary material, figure S3C-F). D.mel-2 cells
were cultured at 258C in Express Fivew serum-free medium
supplemented with antibiotics and 2 mM L-glutamine.
siRNA duplex targeting human AURKA and control
siRNA duplex against GL2 have been previously described
[43] (Sigma-Aldrich).
Transfections were carried out using the Invitrogen
Neonw system to electroporate cells with siRNA or plasmids,
according to the manufacturer’s instructions.
For mitochondrial imaging in living cells, cells were incu-
bated in 100 nMMitoTrackerTM Red CMXRos (Thermo Fisher
Scientific) or Mito-IDw Green (Enzo) diluted in filming
medium (see below) for 15 min. MitoTrackerTM/Mito-IDw
were replaced with fresh filming medium prior to time lapse.
Cells were treated with 100 nM MLN8237 during time-
lapse experiments, by addition of drug in a volume not lessthan 1/100 of the existing dish volume and gentle mixing
of the medium on the dish.
3.3. Cell extracts, fractionation and immunoblotting
Whole-cell extracts were prepared by scraping cells directly
into 2 SDS Sample Buffer with 10 mM DTT. Samples
were syringed to shear DNA or sonicated and boiled at
958C for 5 min prior to SDS-PAGE on 4–12% precast gradient
gels (Invitrogen). Transfer onto Immobilon-P or Immobilon-
FL membranes was carried out using the XCell IITM Blot
Module according to the manufacturer’s instructions. Mem-
branes were blocked in PBS, 0.1% Tween-20, 5% dried milk,
and processed for immunoblotting with the primary anti-
bodies indicated in the figures. Secondary antibodies used
were HRP-conjugated, or IRDyew 680RD- or 800CW-conju-
gated for quantitative fluorescence measurements on an
Odysseyw Fc Dual-Mode Imaging System (LI-COR Bio-
sciences). For cell fractionation experiments, cells were
harvested and treated at 48C with 40 mg ml21 digitonin in
10 mM Tris–HCl (pH 7.4), 100 mM NaCl, 25 mM MgCl2,
1 mM Na3VO4, 1 mM NaF and EDTA-free protease inhibitor
cocktail (Roche). Cells were disrupted by 10 passages through
a 25-gauge needle (whole-cell extract). Cell nucleiwere pelleted
by centrifugation at 3000 r.p.m. for 10 min in a microfuge at
48C. The resulting supernatant was re-centrifuged at 13
000 r.p.m. for 15 min to yield mitochondrial (pellet) and
cytoplasmic (supernatant) fractions.
3.4. Immunofluorescence analysis
Cells were grown on 13 mm glass coverslips, synchronized
and fixed using either 100%MeOH at –208C or 4% PFA treat-
ment at ambient temperature. Mitochondria were detected
using anti-TOMM20 (Santa Cruz), AURKA using anti-
AURKA (rabbit antibody Abcam ab1287 or mouse antibody
BD Transduction Laboratories 610 939) and AURKA-Venus
using anti-GFP (Abcam ab290). Secondary antibodies
used were AlexawFluor 488-anti-rabbit and AlexawFluor
568-anti-mouse (Thermo Fisher Scientific). Cells were stained
according to standard protocols in PBS buffer containing
0.1% Triton X100 and 3% BSA and mounted in ProLongw
Gold antifade (Thermo Fisher Scientific). Images were
captured using an Axiovert 200 M fluorescence microscope
(Carl Zeiss Inc.) with a 100 NA 1.4 oil objective and Cool-
snap HQ2 camera (Photometrics) controlled by the
METAMORPHw software. Images were deconvolved using 10
iterations of the AUTOQuant X2 (Media Cybernetics) blind
deconvolution algorithm and presented as maximum-
intensity projections of 10  0.1 mm stacks using IMAGEJ
(Molecular Devices LLC). Super-resolution images were
acquired on a Deltavision Optical Microscope eXperimental
(OMX) 3D-SIM System V3 and analysed using SOFTWORX
(Applied Precision) and IMAGEJ Volume Viewer plugin. Inten-
sity level, contrast and brightness of images were adjusted
using Adobe PHOTOSHOP where indicated.
3.5. Live cell microscopy
Cells were seeded onto 8-well plastic-bottom slides (Ibidi
GmbH, Martinsried, Germany) at a density of 8  104 cm22.
The imaging medium was Leibowitz L-15 (Thermo Fisher
Scientific) supplemented with FBS and antibiotics as
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9described above. Expression of AURKA-Venus was induced
24 h prior to imaging, which was carried out on an Olympus
CellR widefield imaging platform comprising an Olympus
IX81 motorized inverted microscope, Orca CCD camera
(Hamamatsu Photonics, Japan), motorized stage (Prior Scien-
tific, Cambridge, UK) and 378C incubation chamber (Solent
Scientific, Segensworth, UK) fitted with appropriate filter sets
and a 60 NA 1.42 oil objective. Images were acquired using
the Olympus CELLR software as 1 mm stacks and exported as
12 bit TIFF stacks for display as maximum-intensity projections
in IMAGEJ.
3.6. Mitochondrial morphology analysis
MitoTrackerTM images were analysed using the MICROP soft-
ware [44] to derive measurements of mitochondrial length.
All analyses and statistical significance tests were verified
through a separate manual analysis of the same images using
the lengths of 30 mitochondria per cell, selected by beginning
at the 12 o’clock position and moving clockwise around the
nucleus. MICROP results were plotted in R as kernel density
estimations to derive the presented probability density curves
(see electronic supplementary material, figure S2A). Statistical
significance of probability density distributions were tested
using a two-sample Kolmogorov–Smirnov (K-S) test on the
raw measurements as indicated in figure legends and illus-
trated in the electronic supplementary material, figure S2B.
All results reported in this study were also significant
according to the Mann–Whitney U-test, p, 0.01.Data accessibility. The datasets supporting this article have been
uploaded as part of the electronic supplementary material.
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